PARAGANGLIOMA

This study tests a radioactive drug called Lutathera in teenagers aged 12 to 18 who have rare tumors of the gut, pancreas, or nerve tissue. The goal is to check how safe the drug is and how much radiation reaches organs like the kidneys and bone marrow. About 11 participants will…

This study tests whether a combination of two drugs, talazoparib and temozolomide, can shrink advanced rare cancers or stop them from growing. The trial includes 14 adults with rare solid tumors that have not responded to standard treatments. Talazoparib blocks a protein that hel…

This phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…

This study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 we…

This study tests a daily pill called axitinib in adults with a rare type of adrenal tumor (pheochromocytoma or paraganglioma) that has spread or cannot be removed by surgery. The main goal is to see how many patients' tumors shrink or disappear. Researchers also track how long th…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-DOTATOC to find neuroendocrine tumors (NETs) and other related cancers. The scan targets a molecule found in high amounts on these tumor cells. Researchers want to see if this scan is safer and …